VYNE Therapeutics Inc. filed its 10-K on Mar 14, 2023 for the period ending Dec 31, 2022. In this report its auditor, Baker Tilly, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.51 USD | -0.79% | +1.62% | +7.73% |
Apr. 04 | Transcript : VYNE Therapeutics Inc. - Special Call | |
Feb. 29 | VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.73% | 35.67M | |
+29.68% | 699B | |
+25.07% | 571B | |
-4.35% | 364B | |
+17.65% | 326B | |
+3.77% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.79% | 154B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- VYNE Therapeutics Inc. Auditor Raises 'Going Concern' Doubt